Ingmar Bruns - 02 Dec 2024 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Medical Officer
Signature
/s/ Andrea Paul, attorney-in-fact for Ingmar Bruns
Issuer symbol
ZNTL
Transactions as of
02 Dec 2024
Net transactions value
$0
Form type
4
Filing time
03 Dec 2024, 19:02:41 UTC
Previous filing
13 Nov 2024
Next filing
05 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +712,650 $0.000000 712,650 02 Dec 2024 Common Stock 712,650 $3.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest over a four-year period as follows: 25% of the options will vest on November 13, 2025, with the remaining 75% vesting in substantially equal monthly installments thereafter until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.